

Global Encephalitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

https://marketpublishers.com/r/GB9B3F8720EEN.html

Date: August 2019

Pages: 40

Price: US\$ 1,799.00 (Single User License)

ID: GB9B3F8720EEN

Abstracts

High levels of pipeline activity are being observed in Encephalitis treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including CEL-SCI Corp, Cour Pharmaceutical Development Company Inc, Knight Therapeutics Inc, Olymvax Biopharmaceuticals Inc, Sage Therapeutics Inc and others.

A Significant contribution to the Encephalitis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Encephalitis pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Encephalitis condition and increased access to investments is encouraging growth of Encephalitis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Encephalitis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Encephalitis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2,



phase 3 and pre-registration phases are also analyzed.

The current report examines the current Encephalitis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Encephalitis. Further, orphan drug status, fast track designation, grants awarded and other special status for Encephalitis pipeline compounds are also included. This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Encephalitis pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Encephalitis Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Encephalitis drugs

Late phase: Phase 3 and in-approval Encephalitis drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Encephalitis therapeutic treatment activities



Details for	each	Encephalitis	drug	candidate-

Details for each Encephalitis drug candidate-		
Snapshot		
Drug Name		
Alternative Names		
Company		
Originator		
Phase		
Molecule Type		
Orphan Drug Status		
Drug Overview		
Mechanism of Action		
Current Status		
Trial Details		
Other details		
Pre-clinical trials for each drug candidate		
Clinical trials for each drug candidate		

Recent Encephalitis therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news



Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Encephalitis- Disease Overview
- 2.2 Encephalitis- Pipeline Snapshot
- 2.3 Encephalitis- Pipeline Drugs by Phase
- 2.4 Encephalitis- Pipeline Drugs by Company
- 2.5 Encephalitis- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 CEL-SCI Corp Encephalitis Drug Pipeline, H2- 2019
- 3.2 Cour Pharmaceutical Development Company Inc Encephalitis Drug Pipeline, H2-2019
- 3.3 Knight Therapeutics Inc Encephalitis Drug Pipeline, H2- 2019
- 3.4 Olymvax Biopharmaceuticals Inc Encephalitis Drug Pipeline, H2- 2019
- 3.5 Sage Therapeutics Inc Encephalitis Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Encephalitis- Phase 1 Drug Details
- 4.2 Encephalitis- Phase 1 Drug Overview
- 4.3 Encephalitis- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Encephalitis- Phase 2 Drug Details
- 5.2 Encephalitis- Phase 2 Drug Overview
- 5.3 Encephalitis- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details



6 PHASE 3 PIPELINE DRUG DETAILS

- 6.1 Encephalitis- Phase 3 Drug Details
- 6.2 Encephalitis- Phase 3 Drug Overview
- 6.3 Encephalitis- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Encephalitis- Pre-clinical Phase Drug Details
- 7.2 Encephalitis- Pre-clinical Phase Drug Overview
- 7.3 Encephalitis- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology



I would like to order

Product name: Global Encephalitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In

Approval Therapeutics, Companies and Markets

Product link: https://marketpublishers.com/r/GB9B3F8720EEN.html

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB9B3F8720EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

